SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Okada H, Kawaida N, Ogawa T, Arakawa S, Matsumoto O, Kamidono S. Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. The Kobe University Ym617 Study Group. Scand J Urol Nephrol 1996; 30: 37985
  • 2
    Kurita Y, Masuda H, Suzuki K, Fujita K, Kawabe K. Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy. Br J Urol 1997; 80: 7883
  • 3
    Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 41924
  • 4
    Di Silverio F, Serio M, D’Eramo G, Sciarra F. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study. Eur Urol 1990; 18 (Suppl. 3): 5461
  • 5
    Schellhammer PF, Sharifi R, Block NL et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. The Casodex Combination Study Group. Urology 1997; 50: 3306
  • 6
    Akaza H, Homma Y, Okada K et al. A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up. BJU Int 2003; 91: 336
  • 7
    Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer. results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172: 186570
  • 8
    Kondo Y, Homma Y, Aso Y, Kawabe K, Mieda M, Takahashi H. Relative potency of antiandrogens with reference to intracellular testosterone in the rat prostate. Prostate 1996; 29: 14652
  • 9
    Shibata Y, Fukabori Y, Ito K, Suzuki K, Yamanaka H. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride. J Urol 2001; 165: 28993
  • 10
    Smith CB, Ghanadian R, Chisholm GD. Inhibition of the nuclear dihydrotestosterone receptor complex from rat ventral prostate by antiandrogens and stilboestrol. Mol Cell Endocrinol 1978; 10: 1320
  • 11
    Harada M, Kinoshita Y, Moriyama M et al. Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA). Prostate 1994; 25: 14755
  • 12
    Boccon-Gibod L, Bertaccini A, Bono AV et al. Management of locally advanced prostate cancer: a European consensus. Int J Clin Pract 2003; 57: 18794
  • 13
    Yoshida K, Takeuchi S. Pretreatment with chlormadinone acetate eliminates testosterone surge induced by a luteinizing-hormone-releasing hormone analogue and the risk of disease flare in patients with metastatic carcinoma of the prostate. Eur Urol 1995; 27: 18791
  • 14
    Goya N, Ishikawa N, Ito F et al. Ethanol injection therapy of the prostate for benign prostatic hyperplasia: preliminary report on application of a new technique. J Urol 1999; 162: 3836
  • 15
    Goya N, Ishikawa N, Ito F, Kobayashi C, Tomizawa Y, Toma H. Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results. J Urol 2004; 172: 101720
  • 16
    Plante MK, Folsom JB, Zvara P. Prostatic tissue ablation by injection: a literature review. J Urol 2004; 172: 206
  • 17
    Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly (lactic/glycolic) acid. Chem Pharm Bull (Tokyo) 1988; 36: 1095103
  • 18
    Okada H, Heya T, Ogawa Y, Shimamoto T. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. J Pharmacol Exp Ther 1988; 244: 74450
  • 19
    Shibata Y, Ito K, Suzuki K et al. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 2000; 42: 4555
  • 20
    Terouanne B, Paris F, Servant N, Georget V, Sultan C. Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line. Mol Cellular Endocrinol 2002; 198: 1437
  • 21
    Murakoshi M, Tagawa M, Ikeda R. Atrophic effects of antiandrogen, chlormadinone acetate (CMA) on dog prostate with spontaneous benign prostatic hyperplasia. J Toxicol Sci 2000; 25: 14350
  • 22
    Murakoshi M, Ikeda R, Fukui N. The effects of chlormadinone acetate (CMA), antiandrogen, on the pituitary, testis, prostate and adrenal gland of the dog with spontaneous benign prostatic hyperplasia. J Toxicol Sci 2001; 26: 11927
  • 23
    Kawakami E, Shimizu M, Orima H, Fujita M, Hori T, Tsutsui T. Chlormadinone acetate pellet implantation plus short-term oral administration in dogs with benign prostatic hypertrophy. Int J Androl 1998; 21: 6773
  • 24
    Shibata Y, Ono Y, Kashiwagi B et al. Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate. Urology 2003; 62: 9426
  • 25
    Ukimura O, Kawauchi A, Kanazawa M et al. Preoperative administration of chlormadinone acetate reduces blood loss associated with transurethral resection of the prostate: a prospective randomized study. BJU Int 2005; 96: 98102
  • 26
    Yoshida H, Haraguchi C, Ogawa Y et al. [Clinical effects of chlormadinone acetate (Prostal) on patients with prostatic hypertrophy – with reference to estimation of size and weight of prostate by means of transrectal ultrasonotomography]. Hinyokika Kiyo 1983; 29: 141926
  • 27
    Gotanda K, Shinbo A, Okada M et al. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels. Prostate Cancer Prostatic Dis 2003; 6: 6672
  • 28
    Plante M, Lapointe S, Labrie F. Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. J Steroid Biochem 1988; 31: 614
  • 29
    Ogawa Y, Okada H, Heya T, Shimamoto T. Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals. J Pharm Pharmacol 1989; 41: 43944